OCRX Ocera Therapeutics, Inc.

2.25
+0.05  (2.27%)
Previous Close 2.20
Open 2.20
Price To book 2.69
Market Cap 52.07M
Shares 23,143,000
Volume 314,371
Short Ratio 0.79
Av. Daily Volume 305,322

SEC filingsSee all SEC filings

  1. 8-K - Current report 17515972
  2. 8-K - Current report 162037773
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 161968695
  4. 8-K - Current report 161966453
  5. 8-K - Current report 161957097

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b enrollment completion announced December 7, 2016. Data due 1Q 2017.
OCR-002 (IV)
Hepatic encephalopathy
Phase 2a trial to be initiated 1H 2017.
OCR-002
Cirrhosis

Latest News

  1. OCERA THERAPEUTICS, INC. Files SEC form 8-K, Other Events
  2. Ocera Announces Successful Phase 1 Clinical Study of Orally-Administered OCR-002 in Patients with Cirrhosis
  3. Ocera Announces Successful Phase 1 Clinical Study of Orally-Administered OCR-002 in Patients with Cirrhosis
  4. ETFs with exposure to Ocera Therapeutics, Inc. : December 29, 2016
  5. Ocera Therapeutics (OCRX) Catches Eye: Stock Jumps 6.8%
  6. Coverage initiated on Ocera Therapeutics by H.C. Wainwright
  7. How Cenveo, Inc. (CVO) Stacks Up Against Its Peers
  8. OCERA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  9. Ocera Completes Enrollment of STOP-HE, a Phase 2b Study of OCR-002 in Hospitalized Patients with Hepatic Encephalopathy
  10. OCERA THERAPEUTICS, INC. Financials
  11. Ocera to Present at the Stifel 2016 Healthcare Conference
  12. ETF’s with exposure to Ocera Therapeutics, Inc. : November 4, 2016
  13. Ocera Therapeutics, Inc. :OCRX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 3, 2016
  14. Ocera Therapeutics Reports Third Quarter 2016 Financial Results and Company Update
  15. OCERA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
  16. Ocera Therapeutics Reports Third Quarter 2016 Financial Results and Company Update
  17. Ocera Therapeutics Appoints Biopharmaceutical Veteran Willard Dere, M.D. to Board of Directors
  18. OCERA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
  19. Ocera Therapeutics Appoints Biopharmaceutical Veteran Willard Dere, M.D. to Board of Directors
  20. Ocera Therapeutics Announces Late-Breaker Abstract Accepted for Presentation at the AASLD Liver Meeting 2016

SEC Filings

  1. 8-K - Current report 17515972
  2. 8-K - Current report 162037773
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 161968695
  4. 8-K - Current report 161966453
  5. 8-K - Current report 161957097
  6. 8-K - Current report 161895730
  7. 8-K - Current report 161890870
  8. 8-K - Current report 161887342
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 161807416
  10. 8-K - Current report 161803913